StockNews.com upgraded shares of AC Immune (NASDAQ:ACIU - Free Report) from a hold rating to a buy rating in a report issued on Tuesday morning.
Separately, HC Wainwright lowered their price target on shares of AC Immune from $16.00 to $12.00 and set a "buy" rating for the company in a report on Thursday, May 1st.
Check Out Our Latest Stock Analysis on ACIU
AC Immune Stock Performance
NASDAQ:ACIU traded up $0.14 during trading hours on Tuesday, reaching $1.71. The stock had a trading volume of 90,077 shares, compared to its average volume of 174,314. AC Immune has a 12-month low of $1.43 and a 12-month high of $4.98. The stock has a 50 day simple moving average of $1.76 and a 200 day simple moving average of $2.46. The stock has a market cap of $171.70 million, a P/E ratio of -3.72 and a beta of 1.62.
AC Immune (NASDAQ:ACIU - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.01. The company had revenue of $1.12 million during the quarter, compared to analysts' expectations of $1.99 million. On average, equities analysts expect that AC Immune will post -0.62 earnings per share for the current fiscal year.
Institutional Investors Weigh In On AC Immune
Several institutional investors have recently modified their holdings of ACIU. Geode Capital Management LLC boosted its holdings in AC Immune by 6.4% during the third quarter. Geode Capital Management LLC now owns 58,296 shares of the company's stock worth $220,000 after buying an additional 3,499 shares in the last quarter. Quinn Opportunity Partners LLC bought a new position in AC Immune during the 4th quarter valued at $27,000. Two Sigma Advisers LP bought a new position in shares of AC Immune in the 4th quarter worth about $36,000. Boothbay Fund Management LLC acquired a new stake in shares of AC Immune in the 4th quarter worth about $38,000. Finally, RPO LLC bought a new stake in shares of AC Immune during the 4th quarter worth about $51,000. 51.36% of the stock is owned by hedge funds and other institutional investors.
About AC Immune
(
Get Free Report)
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Further Reading
Before you consider AC Immune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AC Immune wasn't on the list.
While AC Immune currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
